TRON Group Inc (ID) (TGRP)

Anyone buying this? Seems like lumpy low margin revenue...when will it inflect?

$TGRP secured a $50 million contract. This was the company "Alchem Laboratories" that announced a strategic alliance with Mark Cuban Cost Plus Drug Company, in January.

TRON Group Inc. Announces Subsidiary Alchem Laboratories Awarded NIH Contract
TRON Group Inc. (OTC: TGRP) is pleased to announce its subsidiary Alchem Laboratories was awarded
contract #75N98026D00012 “Drug Manufacturing and Formulation Program (DMFP)” a 10-year indefinite
delivery / indefinite quantity (IDIQ) contract with the National Institute of Neurological Disorders and
Stroke (NINDS) at the National Institutes of Health (NIH). The Ceiling (Base + Options) is
$50,000,000.00. The NINDS Drug Manufacturing and Formulation Program (DMFP) supports preclinical
and clinical development of therapeutic candidates, managing the manufacturing, formulation, and supply
chain for neuroscience research. As part of the BPN (Blueprint Neurotherapeutics Network), it helps move
validated hits toward Phase I human clinical trials, covering active pharmaceutical ingredient (API)
production, fill/finish, and regulatory documentation.
https://www.otcmarkets.com/file/company/financial-report/559726/content

X-tosis...added to Alchem's partner list......

It appears that TGRP's subsidiary Alchem Laboratories has added X-tosis to its list of partners sometime within the last week. X-tosis is a pre-clinical biotech that is developing therapeutics and diagnostics that target neurodegenerative diseases.

https://www.alchem.com/partners

https://www.x-tosis.com/

https://www.linkedin.com/company/x-tosis/posts/?feedView=all

TGRP- Alchem Laboratories Corp is making big moves… 🤝

UF Innovate | Accelerate client company Alchem Laboratories has announced a strategic alliance with Mark Cuban Cost Plus Drug Company, PBC to advance the development and delivery of essential medicines. 💊

By leveraging Alchem's expertise in process development for active pharmaceutical ingredients (APIs), the collaboration supports the production of lidocaine and diltiazem using Cost Plus Drugs' automated, AI-driven manufacturing platform. Together, the teams aim to strengthen the supply of medications for anesthesia and heart conditions.

https://www.linkedin.com/posts/alchemlaboratories-markcuban-costplusdrugs-share-7419378280115425280-1NKJ?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAGGEUIBdVDIC1IzaIgfZs3k2p86j1O4Ufs

Shocked that this is not getting more love. They will find it eventually.

$TGRP this is nuts. Look at their partners and companies they collaborate with.
https://www.alchem.com/partners

Alchem can be a value-creating partner for both established and start-up pharmaceutical companies, as well as government programs.  Our current partners and collaborators include:

$TGRP and Mark Cuban $TGRP https://t.co/KaPYrM4v4D— JJ (@JayV80) January 18, 2026

Why isn't this getting more attention?  Seems extremely interesting.
What am I missing??

Andrew MacIsaac's comment about the TGRP PR.......

Andrew MacIsaac is the CEO of Applied Pharmaceutical Innovation. I like his comment about Mark Cuban reviewing the TGRP press release......

It's not every day that we're part of a press release that was reviewed by Mark Cuban. We're very happy to provide our capacity to support access to critical medicines.



https://www.linkedin.com/posts/andrewkieranmacisaac_mark-cuban-cost-plus-drugs-and-alchem-laboratories-activity-7417964499346964480-lbHZ?utm_source=share&utm_medium=member_desktop&rcm=ACoAAA4H080BsTOmwPtjtV0e6baNn8o8N0OaIM0

TGRP **Yes, the partnership between Mark Cuban Cost Plus Drugs and Alchem Laboratories (often referred to as Alchem Lab) is a significant and recent development** — announced just two days ago on **January 15, 2026**. It's being described as a **strategic alliance** aimed at advancing essential medicines, which aligns well with Cost Plus Drugs' mission to improve affordability, transparency, and supply chain reliability for critical drugs.
### Key Details of the Partnership- **Focus Areas**: The alliance is centered on developing and supplying **essential medicine therapeutics**, with a strong emphasis on improving **supply chain resiliency** (addressing drug shortages, which have been a major issue in the US).- **Specific Collaboration**: The parties will work together to supply **86 essential medicines and medical countermeasures**, including **critical care drugs** and **antimicrobials**.- **Prior Collaboration Example**: Alchem has already supported Cost Plus Drugs by providing **process development** for active pharmaceutical ingredients (APIs) in drugs like **lidocaine** (a common anesthetic) and **diltiazem** (a heart medication). Cost Plus Drugs uses a highly automated, AI-integrated manufacturing platform for these.- **Broader Context**: This builds on Alchem's previous alliances (e.g., with Applied Pharmaceutical Innovation in Canada in September 2025 for antimicrobial and essential medicines programs). Both companies retain flexibility to pursue funding and development based on project needs.- **Why It's a Big Deal**:   - It expands Cost Plus Drugs' capabilities beyond distribution and retail generics into more advanced development and manufacturing of high-need drugs.  - It supports the company's push for domestic production, shortage prevention, and lower costs — especially timely amid ongoing industry pressures like drug shortages and calls for transparency.  - The announcement came via a press release distributed widely (e.g., EINPresswire, Akron Beacon Journal, National Law Review), signaling it's positioned as a meaningful step in Cost Plus Drugs' growth strategy.
This isn't a minor or one-off deal — it's framed as a **strategic, long-term alliance** with concrete goals around essential/high-unmet-need medicines. It's one of the more production/manufacturing-focused partnerships for Cost Plus Drugs recently (alongside others like Morris & Dickson for injectables or 9amHealth for obesity drugs).
No major updates or expansions reported since the January 15 announcement (as of today, January 17, 2026). For the full press release, check sources like EINPresswire or Cost Plus Drugs' site/news section.

TGRP https://www.google.com/search?q=Mark+Cuban+&ie=UTF-8&oe=UTF-8&hl=en-us&client=safari&mstk=AUtExfByQ2HkuHWwulkUeh3dgk7k_EGFZVGWneTxRNaNMDYPnPmxf3kT8zEdTAR2DSwnM02lVbGPicAiyndM6QGHp7qXFjMxcXqRuB6q2kQYQrLMvAzTSgi3eSBFM0Mb0GZ9vTo&csui=3&ved=2ahUKEwjD-eqbppOSAxXpCnkGHfEYAy0QgK4QegQIARAB. Recent studies show significant potential Medicare savings, and Cuban is pushing for FDA fee waivers and manufacturing capabilities for essential medicines, battling PBMs for pricing transparency. 

Seems like plenty to get under $.10

Still way under the radar here. Wild.

So the Mark Cuban news is connected to Alchemy. A subsidiary of Trgp? Is it possible to get in now under 10?

If that is accurate than that is the reason why it trades much much thinner than what is listed. 

ANTI-BAGHOLDER...share structure, DTC......

THe CEO owns most the DTC cleared shares?

Yes, I believe that is correct. I don't remember exactly when the DTC number was changed (sometime last year I think), but at some point a bunch of his shares must have been moved into the DTC count. I don't know why that was done. I suppose there is always the chance he did that because he intends at some point to sell some of his shares, but I would be somewhat surprised if he did any significant amount of sales anytime soon.

184M shares outstanding. CEO owns 150.5M shares. So that leaves 33.5M shares out there that are not controlled by the CEO. Also worth noting: of those 33.5M shares there are about 2.5M shares that are/were in the hands of company employees or family/friends of the CEO.

THe CEO owns most the DTC cleared shares?

TGRP...very nice press release.....

TGRP not a skinny one, but this news is interesting to me.

Always nice when these OTC stocks get a chance to form some type of alliance or business relationship with prominent corporations or wealthy individuals. I think when people first look at TGRP they see that 148M DTC number and it can cause some buying hesitation (which is completely understandable). But the CEO owns almost 82% (150.5M shares) of the company, and I am guessing he doesn't have plans to sell his position anytime soon, so that leaves about 33.5M shares out there for investors to fight over. The optics of a 33.5M DTC versus a 148M DTC can make a bit of a difference in how investors view the stock.

Mark Cuban Cost Plus Drugs and Alchem Laboratories Announce Alliance to Advance Essential Medicines

DALLAS, TX, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and Alchem Laboratories Corporation (Alchem) today announced the formation of a strategic alliance to develop essential medicine therapeutics, improving supply chain resiliency.

Cost Plus Drugs is employing a highly automated and flexible manufacturing platform that integrates AI and machine learning for real-time quality assessment and process optimization to produce lidocaine, a widely used anesthetic, and diltiazem, a calcium channel blocker used to treat heart conditions., Alchem provided process development of these APIs for Cost Plus Drugs. Alchem has experience performing process development, scale-up, and GMP manufacturing of over 200 APIs, including the USP APIs amikacin, atropine, carboplatin, ciprofloxacin, cisplatin, dantrolene, dobutamine, dopamine, fluconazole, levofloxacin, linezolid, metronidazole, phentolamine, sulfamethoxazole, trimethoprim, and verteporfin.

Under the terms of the agreement, the parties will also collaborate to supply 86 essential medicines and medical countermeasures including critical care drugs and antimicrobials.

In September 2025, Alchem Laboratories and Applied Pharmaceutical Innovation (API-Canada) announced a Strategic Alliance to advance Antimicrobial and Essential Medicines Programs. This new alliance expands work under that collaboration, providing enhanced and equitable access to antimicrobial agents and essential medicines, with North American onshoring of critical therapies to support public needs. Alchem and API-Canada will initially work on lidocaine and diltiazem vial supply for Canada, as well as antimicrobials and vial manufacturing. As part of the arrangement, API-Canada will also support diltiazem and lidocaine vial supply more broadly as required by the collaborators.

Both Alchem and Cost Plus Drugs maintain the flexibility to pursue funding and development pathways commensurate with project maturity and strategic alignment.

About Mark Cuban Cost Plus Drugs

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,300 prescription products, delivered by mail to thousands of happy customers every day. Customers can also go to participating retail pharmacies to receive Cost Plus Drugs pricing through the Team Cuban Card. Cost Plus Drugs is working with health plans, managed-care organizations, PBMs, and self-insured employers to bring these same savings to benefit plans nationwide. Learn more at www.markcubancostplusdrugcompany.com.

Dr. Alex Oshmyansky, CEO
Mark Cuban Cost Plus Drugs
press@costplusdrugs.com

About Alchem Laboratories Corporation

Alchem Laboratories Corporation is a pharmaceutical development company dedicated to advancing therapies in areas of high unmet medical need, with an emphasis on accessible, high-quality essential medicines. Alchem is a subsidiary of TRON Group Inc. (OTC:TGRP).

Dr. James D Talton, CEO
Alchem Laboratories Corporation
info@alchem.com

About Applied Pharmaceutical Innovation

Applied Pharmaceutical Innovation is one of Canada’s largest not-for-profit life sciences commercialization organizations. Headquartered in Edmonton, Alberta, Applied Pharmaceutical Innovation works to accelerate the development, manufacturing, and commercialization of life sciences products, and is home to Canada’s largest security of supply initiative.
Jenna Bienert
Applied Pharmaceutical Innovation
communications@appliedpharma.ca

Has to be the Mark Cuban news?

TGRP not a skinny one, but this news is interesting to me.
Mark Cuban Cost Plus Drugs and Alchem Laboratories Announce Alliance to Advance Essential Medicines
https://www.einpresswire.com/article/883463989/mark-cuban-cost-plus-drugs-and-alchem-laboratories-announce-alliance-to-advance-essential-medicines

https://clinicaltrials.gov/study/NCT04234568
Study Completion (Estimated) 2026-03-14

https://clinicaltrials.gov/study/NCT05724108
Study Completion (Estimated) 2025-11-30

This one keeps chugging along... Catalysts?

https://news.med.miami.edu/dr-aman-chauhan-presents-phase-1-study-on-neuroendocrine-tumors-at-esmo-2025/
https://www.msn.com/en-us/news/other/research-targets-treatment-resistance-in-neuroendocrine-tumors/ar-AA1OSgCv

https://www.otcmarkets.com/stock/TGRP/news/ESMO-Abstract-1709MO---Multi-center-NCI-sponsored-phase-I-study-of-triapine-in-combination-with-177Lu-dotatate-in-patien?id=495726

Couple of items from the last 2 weeks.....

1) Alchem Laboratories was awarded a contract this week (September 15) from the National Institute of Allergy and Infectious Diseases. It is a 7-year contract with a $50M ceiling value.

https://www.fpds.gov/ezsearch/search.do?q=%22Alchem+laboratories%22&s=FPDS.GOV&templateName=1.5.3&indexName=awardfull&sortBy=SIGNED_DATE&desc=Y

2) Alchem Laboratories announced on September 3 that it has formed a strategic alliance with Applied Pharmaceutical Innovation. I think this is a pretty interesting development that TGRP should have done a better job of promoting. I'm not sure why they chose not to put this press release on the company website and OTC Markets.

Alchem Laboratories and Applied Pharmaceutical Innovation (API) Forge Strategic Alliance to Advance Antimicrobial and Essential Medicines Programs

ALACHUA, FL, UNITED STATES, September 3, 2025 /EINPresswire.com/ -- Alchem Laboratories Corporation (“Alchem”) and Applied Pharmaceutical Innovation Ltd. (“API”) today announced the formation of a strategic alliance to explore and advance joint initiatives in the fields of antimicrobials and essential medicine therapeutics, improving supply chain resiliency.

Working with as a secondary site for Alchem’s Florida-based active pharmaceutical ingredient manufacturing for U.S. government contracts including the National Institutes of Health and United States Department of Defense, API’s Canadian-funded security of supply capacity can be brought to bear if needed, providing critical redundancy, while enabling the growth of US-based supply chains.

Under the terms of the agreement, the parties will also collaborate on promising programs and the ability to move forward with respect to future funding proposals and R&D efforts. This structure enables both parties to evaluate opportunities for 2025-2026 to focus on drug shortage requirements.

The alliance is oriented toward the non-commercial advancement of antimicrobial agents and essential medicines to filing-ready status, with particular emphasis on ensuring equitable access to critical therapies.

As initial candidate projects, Alchem and API are proposing to supply products from “Essential Medicines” referenced in ASPR’s 2022 list of 86 essential medicines and medical countermeasures for the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR).

“API’s Canadian Critical Drug Initiative is a $200 million investment into capacity that is specifically designed with these sorts of collaborations in mind,” say API CEO, Andrew MacIsaac, “we’re able to significantly improve supply chain resiliency, without distorting the market, while also enabling partners like Alchem to build domestic supply.”

“We’re very pleased to announce this next step in Alchem’s growth,” says Alchem CEO, James Talton, “as a Florida-based active pharmaceutical ingredient manufacturer we’ve been a supplier of choice for industry and government. This project with API expands our capabilities and enables us to bring a stronger offering to bear as we work to improve the US-based manufacturing sector.”

This alliance underscores Alchem’s and API’s shared mission to enhance pharmaceutical innovation in critical therapeutic areas and to better support access to essential treatments.

Both Alchem and API maintain the flexibility to pursue funding and development pathways commensurate with project maturity and strategic alignment.

About Alchem Laboratories Corporation

Alchem Laboratories Corporation is a pharmaceutical development company dedicated to advancing therapies in areas of high unmet medical need, with an emphasis on accessible, high-quality essential medicines.

About Applied Pharmaceutical Innovation (API)

API is one of Canada’s largest not-for-profit life sciences commercialization organizations. Headquartered in Edmonton, Alberta, API works to accelerate the development, manufacturing, and commercialization of life sciences products, and is home to Canada’s largest security of supply initiative.

Contact:
Jenna Bienert
Applied Pharmaceutical Innovation
communications@appliedpharma.ca
James Talton, President and CEO
Alchem Laboratories Corporation
info@alchem.com

https://www.einpresswire.com/article/845341323/alchem-laboratories-and-applied-pharmaceutical-innovation-forge-strategic-alliance-to-advance-antimicrobial-programs

Applied Pharmaceutical Innovation website.....

https://appliedpharma.ca/

Applied Pharmaceutical Innovation's LinkedIn post regarding the alliance with Alchem Laboratories.....


https://www.linkedin.com/posts/applied-pharmaceutical-innovation_were-pleased-to-announce-our-new-partnership-activity-7369376286101704705-HVgh/

https://www.einnews.com/pr_news/830531458/nanopharmaceutics-announces-end-of-patient-recruitment-for-nci-phase-ii-study-with-triapine-for-neuroendocrine-tumors

I finally got out today, there was some decent dilution for the last few months. With tiny bit of profits nothing to brag about only 34,000 shares at 2 cents and finally sold it today at 3 cents. Good luck everyone.

https://www.einpresswire.com/article/811095507/nanopharmaceutics-announces-nanodox-hydrogel-will-be-tested-in-the-university-of-western-australia-clinical-trial

It looks like it's getting ready to go...

Thanks dino, good to hear from you friend!!

I am too Trademax.

Still holding my core position. We'll see what transpires in time.

I am still here. Just waiting on that one big news.

So nothing of real consequence it seems but hey I'll take the trading action no problem. Would love to see it up back where it was.

Name change filed with OTC.

TRON Pharmaceuticals, Inc. (TGRP) Changes Corporate Name back to TRON Group Inc.
On February 3, 2025 - TRON Pharmaceuticals, Inc. (OTC Pink: TGRP) (the "Company") is pleased to announce its Nevada corporation name change back to "TRON Group Inc." (the "Name Change") effective January 29, 2025. The company name and OTC trading symbol will remain unchanged and is in compliance with FINRA requirements. TRON Group Inc. subsidiaries include Nanopharmaceutics, Inc., a wholly-owned subsidiary, and Alchem Laboratories Corporation, a majo

Little bit of action here today. Did something occur to get us moving again? don't think I have seen those phase III results yet.

You did? 

No one has posted here in 6 weeks?

I was pretty successful at redirecting some TNXP people here the other day and tried again with NUKK yesterday to no avail. Honestly it would take like 10k for this thing to start a parabolic move. Just need the eyes on it but I'm glad my messaging helped revive it some this week. Otherwise it's radio silence everywhere on this guy.

This stock just FEELS good! Like it's gonna pop at any time now!

$TGRP https://www.nanopharmaceutics.com/team

@grubstake Didn't wanna muddy the other board up with a discussion about another stock but just fyi the description on the OTC market page is just incorrect. This has been operating as Tron Pharmaceuticals for awhile. I can't speak to why that page still has them listed incorrectly but if you go through the thread here there are tons of links proving this to be the case.

https://www.otcmarkets.com/stock/TGRP/news/Nanopharmaceutics-Inc-TGRP-Changes-Corporate-Name-back-to-TRON-Group-Inc-and-forms-wholly-owned-Nanopharmaceutics-Subsid?id=443102

The beauty of this thing is, there is no dilution and the whole family owns the stock. I am just not paying attention, just saw this one my portfolio and said impressive move. Impressive pipeline and impressive CEO with a PHD, not some share selling scheme. I think this will hit a minimum $1.50 in due time, just needs patience.

Ya just hoping the trend of today continues. This one really doesn't need much volume at all to fly. We really didn't have huge volume or money spent here today and it still rose 90%. We will see what the rest of the week brings and if we can keep building this one up.

Good job bud. I was in TNXP from 28 cents to 1.29 fast from the day before, with 40,000 shares, it was a very good score. Right now this range is trading just tad bit over my average, I am going to be patience with this one for sure.

Did a lot of ground work today directing people from tnxp over here and it seemed to have worked a good bit to get some new people on board with this one.

Fantastic move, still have my shares. Waiting for dollars. Only 34,000 shares. I don't need this, so waiting is the best approach.

It's in English but a Translator might be needed.

What is this? A PR or what?
https://www.otcmarkets.com/stock/TGRP/news/PRX-3140-a-5-HT4-Agonist-and-Sigma-1-AgonistAntag-Modulates-Glucocorticoid-Insulin-Suppression-and-Cortisol-Levels?id=462201

Yeesh man take it easy. Its clearly getting some more attention today. Doesn't always have to be swinging millions of dollars to make money. Not everyone can play with huge sums of money but if it runs again like it did then some people absolutely can. Besides, like I said, its more about what they are doing here. That's why I invested and I want to see it be successful. Effective cancer drugs make a big difference in a lot of peoples lives and I am happy to put my money in a company developing drugs like that vs getting them on the hook for drugs they don't need.